Site #322 — Newport Beach, California

Site #322 is a clinical research site located in Newport Beach, California, United States 92663.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Site #322 has participated in 1 clinical trials.

Therapeutic areas: Presbyopia, Near Vision, Refractive Error.

Sponsors: LENZ Therapeutics, Inc.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Newport Beach

Browse all research sites in California · View every site in Newport Beach

• Hoag Memorial Hospital - Hoag Cancer Center
• Hoag Hospital Site#110
• 840-01 - HOAG Memorial Hospital
• Hoag Memorial Hospital - Center for Research & Education
• Hoag Cancer Center at Hoag Memorial Hospital Presbyterian
• University of California, Irvine Medical Center
• Hoag Hospital
• Hoag Memorial Hospital Presbyterian (Site 080-026), One Hoag Drive
• Premier Cardiology, Inc / Hoag Hospital
• Hoag Memorial Hospital Presbyterian /ID# 274364
• Hoah Memorial Hospital Presbyterian
• Hoag Memorial Hospital Site#115

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Site #322?

Site #322 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Site #322 conducted?

Site #322 has 1 clinical trials on record. Their work covers Presbyopia, Near Vision, Refractive Error.

Is Site #322 accredited by Crixeo Clinical Trials?

Site #322 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Site #322?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.